Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marie-Louise Wiesel

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Bulletin De L'Academie Nationale De Medecine|October 15, 2003
[Platelets and arterial thrombosis]Jean-Pierre Cazenave, Christian Gachet, François Lanza, et al.
Archives of Dermatology|March 19, 2008
Between light and dark, the chimera comes outDan Lipsker, Elisabeth Flory, Marie-Louise Wiesel, et al.
Transfusion|June 3, 2016
Hemostatic properties and protein expression profile of therapeutic apheresis plasma treated with amotosalen and ultraviolet A for pathogen inactivationPhilippe Ohlmann, Béatrice Hechler, Philippe Chafey, et al.
Thrombosis and Haemostasis|September 28, 2006
Plasma glycoprotein V levels in the general population: normal distribution, associated parameters and implications for clinical studiesBoris Aleil, Nicolas Meyer, Valérie Wolff, et al.
Stroke|February 5, 2005
Soluble platelet glycoprotein V is a marker of thrombosis in patients with ischemic strokeValérie Wolff, Boris Aleil, Maurice Giroud, et al.
JACC. Cardiovascular Interventions|July 16, 2010
Impact of P2Y12 inhibition by clopidogrel on cardiovascular mortality in unselected patients treated by percutaneous coronary angioplasty: a prospective registrySoraya El Ghannudi, Patrick Ohlmann, Nicolas Meyer, et al.
Transfusion|January 16, 2008
Photochemical treatment of plasma with amotosalen and UVA light: process validation in three European blood centersPeter Schlenke, Tor Hervig, Hervé Isola, et al.
Transfusion|September 21, 2010
Use of additive solutions and pathogen inactivation treatment of platelet components in a regional blood center: impact on patient outcomes and component utilization during a 3-year periodJean-Pierre Cazenave, Hervé Isola, Chantal Waller, et al.
Journal of the American College of Cardiology|January 22, 2011
Cardiovascular mortality in chronic kidney disease patients undergoing percutaneous coronary intervention is mainly related to impaired P2Y12 inhibition by clopidogrelOlivier Morel, Soraya El Ghannudi, Laurence Jesel, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Bulletin De L'Academie Nationale De Medecine|October 15, 2003
[Platelets and arterial thrombosis]Jean-Pierre Cazenave, Christian Gachet, François Lanza, et al.
Archives of Dermatology|March 19, 2008
Between light and dark, the chimera comes outDan Lipsker, Elisabeth Flory, Marie-Louise Wiesel, et al.
Transfusion|June 3, 2016
Hemostatic properties and protein expression profile of therapeutic apheresis plasma treated with amotosalen and ultraviolet A for pathogen inactivationPhilippe Ohlmann, Béatrice Hechler, Philippe Chafey, et al.
Thrombosis and Haemostasis|September 28, 2006
Plasma glycoprotein V levels in the general population: normal distribution, associated parameters and implications for clinical studiesBoris Aleil, Nicolas Meyer, Valérie Wolff, et al.
Stroke|February 5, 2005
Soluble platelet glycoprotein V is a marker of thrombosis in patients with ischemic strokeValérie Wolff, Boris Aleil, Maurice Giroud, et al.
JACC. Cardiovascular Interventions|July 16, 2010
Impact of P2Y12 inhibition by clopidogrel on cardiovascular mortality in unselected patients treated by percutaneous coronary angioplasty: a prospective registrySoraya El Ghannudi, Patrick Ohlmann, Nicolas Meyer, et al.
Transfusion|January 16, 2008
Photochemical treatment of plasma with amotosalen and UVA light: process validation in three European blood centersPeter Schlenke, Tor Hervig, Hervé Isola, et al.
Transfusion|September 21, 2010
Use of additive solutions and pathogen inactivation treatment of platelet components in a regional blood center: impact on patient outcomes and component utilization during a 3-year periodJean-Pierre Cazenave, Hervé Isola, Chantal Waller, et al.
Journal of the American College of Cardiology|January 22, 2011
Cardiovascular mortality in chronic kidney disease patients undergoing percutaneous coronary intervention is mainly related to impaired P2Y12 inhibition by clopidogrelOlivier Morel, Soraya El Ghannudi, Laurence Jesel, et al.
Pageof 1